SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, announced today that Drs. JY Gaubert, P Chevallier, and V Vidal, leading French researchers, presented the successful results of their animal study utilizing the MicroThermX® Microwave Ablation System (MicroThermX) at CIRSE 2014. The study was sponsored by Terumo Europe N.V. The objective of the study was to determine reproducibility of the ablation volumes in liver and lung animal studies using the MicroThermX. The researchers examined the results of 18 liver ablations and 24 lung ablations and concluded that ablation volumes generated with the MicroThermX were reproducible in in-vivo liver and lung tissues.
“The positive results of this study reflect BSD’s and Terumo Europe N.V.’s ongoing, long-term commitment to drive innovation and expand treatment options for patients,” said Sam Maravich, Vice President of International Sales and Marketing at BSD Medical. “This study, and others to follow, could help pave the way for our MicroThermX system to be adopted by hospitals and treatment centers all over the world. Microwave ablation therapy has the potential to improve treatment outcomes and quality of life for patients.”
The study, “In vivo experimental evaluation of ablation volumes obtained by microwave in the lung and liver with MicroThermX,” was conducted by the Department of Adult Radiology at Timone University in Marseille, France; the Department of Radiology at University Hospital L’Archet in Nice, France; and the Laboratory of Experimental and Interventional Imagining at Aix-Marseille University, leading research institutions in France.
About the MicroThermX® Microwave Ablation System
The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator.
The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by MicroThermX BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream.
The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency (RF). BSD’s product lines include ablation and hyperthermia treatment systems. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical’s website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts, including statements relating to our 2015 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.